PMID- 37304518
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 0974-7796 (Print)
IS  - 0974-7834 (Electronic)
IS  - 0974-7796 (Linking)
VI  - 15
IP  - 2
DP  - 2023 Apr-Jun
TI  - Electronic medical records-based retrospective, longitudinal, observational study 
      to understand the patient management of benign prostatic hyperplasia with 
      alpha-blockers monotherapy in Indian population.
PG  - 138-147
LID - 10.4103/ua.ua_114_21 [doi]
AB  - OBJECTIVE: The present retrospective study evaluates the effectiveness and 
      tolerability of alpha-blockers as monotherapy in patients with benign prostatic 
      hyperplasia associated with lower urinary tract symptoms (LUTS). MATERIALS AND 
      METHODS: A total of 335 male patients >50 years were categorized into four groups 
      (Alfuzosin: 166, Silodosin: 67, Tamsulosin: 70, Prazosin: 32). The efficacy 
      evaluated as a change in International Prostate Symptom Score (IPSS), peak flow 
      rate (Qmax), residual urine volume, and relief from LUTS, and tolerability of the 
      various alpha-blockers was assessed across the study group. RESULTS: At baseline, 
      most of the patients in alfuzosin (60%), silodosin (77%), and tamsulosin (90%) 
      groups presented with severe IPSS (20-35), whereas patients in the prazosin group 
      (69%) presented with a moderate score. At the end of the study, the mean IPSS 
      gradually improved to moderate (41%, 62%, 66%, and 28%) and mild (59%, 38%, 28%, 
      and 72%) in the alfuzosin, silodosin, tamsulosin, and prazosin groups, 
      respectively (P = 0.004), with improvement in mean change in residual urine 
      volume and complete relief from LUTS symptoms with no surgical or radiological 
      interventions. Overall, 194 adverse events (AEs) were observed in 38.8% of 
      patients. Of the total AEs, patients in the alfuzosin, silodosin, tamsulosin, and 
      prazosin groups experienced 21%, 22%, 39%, and 18% of AEs, respectively. 
      CONCLUSION: The nonselective alpha-adrenergic receptor antagonist, alfuzosin, 
      emerged as noninferior in effectiveness and superior in tolerability than other 
      selective alpha-blockers, silodosin, tamsulosin, and prazosin.
CI  - Copyright: (c) 2023 Urology Annals.
FAU - Gupta, Rahul
AU  - Gupta R
AD  - Department of Urology, Government Medical College, Jammu, Jammu and Kashmir, 
      India.
FAU - Trivedi, Sameer
AU  - Trivedi S
AD  - Department of Urology, IMS-BHU, Varanasi, Uttar Pradesh, India.
FAU - Vaddi, Surya Prakash
AU  - Vaddi SP
AD  - Medical Affairs, Yashoda Hospitals, Hyderabad, Telangana, India.
FAU - Borgohain, Mrinal
AU  - Borgohain M
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
FAU - Mittal, Rajan
AU  - Mittal R
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
FAU - Pandit, Sucheta
AU  - Pandit S
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
FAU - Mane, Amey
AU  - Mane A
AD  - Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
LA  - eng
PT  - Journal Article
DEP - 20230116
PL  - India
TA  - Urol Ann
JT  - Urology annals
JID - 101510823
PMC - PMC10252785
OTO - NOTNLM
OT  - Alpha-blockers
OT  - benign prostatic hyperplasia
OT  - international prostatic symptom score
OT  - lower urinary tract symptoms
OT  - real-world evidence
COIS- There are no conflicts of interest.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/12 06:43
PMCR- 2023/04/01
CRDT- 2023/06/12 04:10
PHST- 2021/06/28 00:00 [received]
PHST- 2021/10/18 00:00 [revised]
PHST- 2021/10/25 00:00 [accepted]
PHST- 2023/06/12 06:43 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:10 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - UA-15-138 [pii]
AID - 10.4103/ua.ua_114_21 [doi]
PST - ppublish
SO  - Urol Ann. 2023 Apr-Jun;15(2):138-147. doi: 10.4103/ua.ua_114_21. Epub 2023 Jan 
      16.